Search
Sysmex España
España | ES
Empresa
Empresa
Back
Empresa
¿Qué hay detrás de Sysmex?
¿Qué hay detrás de Sysmex?
Back
Calidad y sostenibilidad
Calidad y sostenibilidad
Back
Noticias y eventos
Noticias y eventos
Back
Carrera en Sysmex
Carrera en Sysmex
Back
Contacto
Contacto
Back
Nuestros productos
Nuestros productos
Back
Nuestros productos
Oncología
Oncología
Back
Diagnóstico
Diagnóstico
Back
Citometría de flujo
Citometría de flujo
Back
Soluciones Integradas
Soluciones Integradas
Back
Servicios
Servicios
Back
Servicios
Consultoría
Consultoría
Back
Filiales Sysmex
Filiales Sysmex
Back
Control de calidad
Control de calidad
Back
Centro de documentación
Centro de documentación
Back
Academia
Academia
Back
Academia
Centro de conocimiento
Centro de conocimiento
Back
Clínica y laboratorio
Clínica y laboratorio
Back
Formación
Formación
Back
Biblioteca
Biblioteca
Back
Menu
Headquarters
Sysmex Group Companies
Select your local website
Sysmex España Empresa Noticias y eventos Noticias
  • All Years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
Reset filters
2024/09/09 | PRODUCT

La Fundació Puigvert valida una nueva herramienta capaz de seleccionar en 45 minutos el antibiótico más adecuado para infecciones urinarias no complicadas

En un avance significativo para la medicina diagnóstica, un nuevo estudio clínico ha demostrado la eficacia del sistema de análisis Sysmex PA-100 AST, capaz de detectar bacteriuria, es decir la presencia de bacterias en la orina, y efectuar pruebas de sensibilidad antimicrobiana (AST) en tan solo 45 minutos. Esta tecnología, evaluada por primera vez en la Fundació Puigvert, promete transformar el diagnóstico y tratamiento de infecciones del tracto urinario (ITU) y, así, optimizar el uso de antibióticos y reducir la propagación de la resistencia a los antimicrobianos.
more
2024/06/13 | CORPORATE

Sysmex’s PA-100 AST System for Rapid Detection of Antimicrobial Susceptibility Wins One of the UK’s Biggest Science Prizes “Longitude Prize on AMR”

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) is pleased to announce that its subsidiary Sysmex Astrego AB (HQ: Uppsala, Sweden) has been awarded one of the UK's biggest science prizes, the “Longitude Prize on AMR,” for the development of the PA-100 AST System, a rapid antimicrobial susceptibility testing system. The prize is designed to reward and support teams of innovators who have undertaken the challenge of transforming the conventional clinical workflows for infectious diseases, thereby making greatest contribution to tackling the global issue of antimicrobial resistance (AMR).1 Since the prize launched in November 2014, more than 250 teams from around the world have applied, with Sysmex Astrego AB standing out as the sole recipient.
more
2024/04/02 | CORPORATE

Sysmex establishes new branch office in Finland

Strengthening Sysmex’s market presence in Scandinavia
more
2024/02/06 | CORPORATE

Sysmex and CellaVision Expand Alliance with a View to Advancing Hematology Solutions

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) announced today that the Company had entered a strategic alliance agreement (the “Agreement”) with CellaVision AB (HQ: Lund, Sweden; President & CEO: Simon Østergaard) to advance hematology solutions by expanding its portfolio, including next-generation cell morphology analyzers. Going forward, the companies will work to further increase efficiency and standardization of the testing workflow in the hematology field, increase the precision of cell morphology classification, and provide value in supporting diagnosis.
more
2024/02/01 | CORPORATE

Strengthening the Direct Sales and Service System for Business Expansion in Italy

Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) is to commence direct sales and service in Italy in the fields of hematology, urinalysis, and hemostasis, which will be in addition to our direct sales and service in the fields of life science and industrial flow cytometry (FCM)1 that we are already providing. We will expand our business in Italy by increasing our share of the market in various test fields, and also by offering solutions to diverse issues in medical settings through direct communication with our customers.
more
2023/10/11 | CORPORATE

Sysmex Egypt works together with the Ministry of Health to commence early screening programme for colorectal cancer

Having announced the partnership at an official press conference on Sep 10, 2023, Sysmex Egypt and the Egyptian Ministry of Health are celebrating the launch of a vital strategic project that will change people’s lives and secure the future of high-quality colorectal cancer screening technology for the people of Egypt.
more
2023/08/28 | CORPORATE

Sysmex Europe Introduces Caresphere Academy

Sysmex Europe proudly unveils its renamed Caresphere Academy, an innovative in-person and online platform for healthcare education. The new name reflects Sysmex’s commitment to modern professional healthcare advancement and training.
more
2023/07/14 | PRODUCT

Sysmex Europe SE launches XR-Series, the new flagship product line for laboratory haematology

XR-Series is the new flagship haematology analyser product line from Sysmex Europe SE. It builds on the well-known reliability and world-class technology of the XN-Series, its predecessor.
more
2023/04/24 | PRODUCT

Sysmex Europe distributes MammaTyper®, an advanced breast cancer diagnostic assay, through the European distribution agreement with Cerca Biotech

MammaTyper®, an advanced breast cancer diagnostic assay will be distributed in EMEA as a part of the Sysmex Life Science portfolio according to agreement between Sysmex Europe and Cerca Biotech.
more
2023/03/13 | PRODUCT

Sysmex Life Science expands its product portfolio with the SENTiFIT® 800 Analyser – a totally automated and high throughput analyser for faecal immunochemical testing

Sentinel Diagnostics, an Italian company focused for more than 40 years on the development and production of in vitro diagnostics for the most advanced clinical chemistry, immunochemistry, molecular diagnostics and chromatography platforms, announced the launch of the SENTiFIT® 800 Analyser, a fully automated and high throughput system for faecal immunochemical test (FIT). Through Sysmex, the SENTiFIT® 800 Analyser will be distributed throughout EMEA as part of the FIT offering.
more
2023/03/08 | CORPORATE

Sysmex and Siemens Healthineers Establish Global Agreement to Supply Hemostasis Instruments and Reagents as OEMs

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO, Hisashi Ietsugu) announced that, on February 28, 2023, it signed a global OEM agreement on hemostasis products with Siemens Healthcare Diagnostics Inc. (HQ: NY, U.S.A.) (“Siemens Healthineers”) under which each company will supply the other with their products in the diagnostic field of hemostasis on an OEM basis.
more
2023/03/02 | CORPORATE

From Neumünster to the world: Reagents from Sysmex

Medical professionals in doctors' practices and hospitals take blood or urine samples every day and send them to laboratories for analysis. Especially for blood samples, it is highly likely that they are analysed with a Sysmex analyser. At the Neumünster site, the company Sysmex Europe SE produces the necessary reagents and distributes them worldwide. They are used, among other things, in the analysis of blood and urine samples in the Sysmex analysers.
more
2022/11/03 | PRODUCT

OGT launches SureSeq™ Myeloid Plus panel and Universal NGS Complete Workflow

Launch of several new solutions to support OGT’s growing NGS portfolio
more
2022/10/03 | CORPORATE

Sysmex and JCR Pharmaceuticals Establish a Joint Venture in the Field of Regenerative Medicine and Cell Therapy

Aiming for the Research & Development and Early Commercialization of Regenerative Medicine Products Using Stem Cells, etc.
more
2022/09/30 | CORPORATE

Sysmex inaugura su filial en Portugal

more
2022/08/01 | CORPORATE

Pilot, Inc. Becomes Wholly-owned Sysmex Subsidiary Through the Acquisition of Outstanding Shares

Reinforcing Software Design and Development Capabilities
more
2022/06/10 | CORPORATE

Bayerische Hausbau and MATRIX lay the foundation stone for the new work campus FLOW in Hamburg

The new work campus FLOW in Hamburg is becoming a reality: The MATRIX Group and Bayerische Hausbau laid the foundation stone today together with anchor tenant Sysmex Europe and the Second Mayor Katharina Fegebank.
more
2022/05/27 | CORPORATE

The Ajinomoto Foundation, Sysmex, and NEC initiate a cross-industry co-creation project to improve maternal and child health and nutrition in the Republic of Ghana

Contributing to Universal “Nutrition” Health Coverage
more
2022/02/15 | CORPORATE

Sysmex Establishes Subsidiary in Saudi Arabia

Reinforcing Sales, Service, and Support Structures to Expand Business in a Growing Market
more
2022/01/18 | CORPORATE

Sysmex R&D Center Europe and “academist” begin collaborating in providing academic research funds in Europe

“academist” and Sysmex R&D Center Europe collaborate in exploring and granting academic research in Europe in the healthcare area at the European universities’ research labs. Scientific researchers can apply for the research funds through academist’s website.
more
2021/12/08 | CORPORATE

Discover the fighter in you – through our latest antimicrobial resistance (AMR) awareness campaign!

The 2021 #AMRfighter campaign to raise awareness of antimicrobial resistance shows us that making small changes can make a big difference to help mitigate the growing problem.
more
2021/10/15 | CORPORATE

Sysmex Europe wins awards in the programme ‘Excellence in learning 2021’ by Brandon Hall Group

Following the success in 2019, Sysmex Europe receives two bronze awards for ‘Best customer training program’ and ‘Best advance in creating a learning strategy’ by the Brandon Hall Group this year.
more
2021/09/14 | PRODUCT

Sysmex launches its Sample Preparation System PS-10 in EMEA – a new product to make clinical flow cytometry testing more efficient

Sysmex Europe GmbH announces the launch of the automated flow cytometry sample preparation system PS-10 in the EMEA region.
more
2021/06/07 | CORPORATE

Patient stratification and prognostic scores – the value of routine diagnostic parameters in supporting COVID-19 disease management

Identification of COVID-19-positive patients upon hospital admission usually relies on RT-PCR tests, however, clinicians can utilise diagnostic information to make decisions during the first examination of a patient as well. If risk factors are already known, this can be combined with laboratory tests to provide an informed initial evaluation.
more
2021/02/03 | CORPORATE

Sysmex establishes new subsidiary in Portugal

Increasing Portuguese Market Presence by Enhancing Sales and After-Sales Support Networks
more
2020/12/11 | CORPORATE

Sysmex EMEA’s first virtual congress, Sysmex Expo 2020 – a great success!

From 8-10 December, Sysmex EMEA hosted their first ever virtual congress.
more
2020/12/03 | PRODUCT

Sysmex Launches Surgical Robot Unit, hinotori™ Surgical Robot System

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announced today that it will launch the hinotori Surgical Robot System, a surgical robot unit, and the HF Series Instrument, a reusable active endotherapy device (collectively referred to as "hinotori" hereinafter; manufacturer: Medicaroid Corporation [HQ: Kobe, Japan; President: Kaoru Asano]) on December 4, 2020 for medical institutions in Japan.
more
2020/11/05 | CORPORATE

"Conquering the wave" – preparing for the second wave of COVID-19

Sysmex Global Webinar for COVID-19
more
2020/10/09 | CORPORATE

Sysmex Europe is celebrating 40 years of diagnostic advancement and growth

Sysmex Europe GmbH celebrates 40 years of business in EMEA and looks forward to continuing lighting the way with diagnostics.
more
2020/08/19 | CORPORATE

Actualización e información sobre COVID-19

more
2020/03/27 | PRODUCT

Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method)

Aiming for early introduction of test kits forin vitrodiagnostic medical devicesin medical institutions
-Japanese market only-
more
2020/03/05 | CORPORATE

Sysmex Presents Academic Report Related to the Clinical Utility of RAS Gene Mutation Testing for Colorectal Cancer Using Liquid Biopsy

Details of Report on Clinical Utility of OncoBEAM™ RAS CRC Kit presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2020 (ASCO-GI 2020)
more
2020/02/10 | PRODUCT

Magseed® magnetic marker approved for any soft tissue and long-term implantation across Europe

Endomag has received an extended indication for the long-term use of the Magseed® magnetic marker in any soft tissue. The extended indication was approved after the Magseed® marker was found to be accurate and easy to place in the breast and the armpit in a number of clinical studies. CE certification widening follows the 510(k) clearance from the U.S. Food and Drug Administration (FDA), which was received for the same indication already in 2018.
more
2020/01/29 | CORPORATE

Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has reached an agreement to invest in Astrego Diagnostics AB (HQ: Uppsala, Sweden; CEO: Ove Öhman). Through this investment, Sysmex aims to help commercialize a rapid drug susceptibility test that Astrego is developing for urinary tract infections.
more
2020/01/14 | PRODUCT

Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland

Hitado GmbH (Hitado), a Sysmex point-of-care subsidiary, and SphingoTec GmbH (sphingotec) have signed an exclusive distribution agreement for the commercialisation of the Nexus IB10 diagnostic platform by Hitado in Germany. Further, Sysmex Suisse AG will commercialise the platform in Switzerland.
more
2020/01/14 | CORPORATE

Sysmex gives back – supporting social development together

Science and diagnostics are fascinating – at least that’s what we at Sysmex believe. When the opportunity comes along to fuel excitement for science together with other knowledge providers, we take it.
more
2019/12/20 | PRODUCT

OSNA for lung cancer – the newest addition to our oncology portfolio

OSNA, a molecular assay for accurate detection of lymph node metastases, is now available for lung cancer!
more
2019/12/02 | CORPORATE

Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood

Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
more
2019/11/29 | CORPORATE

Sysmex Europe GmbH wins Silver Technology Award from the 2019 Learning In Practice Awards Program by Chief Learning Officer magazine.

Learning awards seem a little bit like in the movie industry – you may get one in one category, but there are always more categories where you can win!
more
2019/11/07 | CORPORATE

Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31

Sysmex’s announced today the financial results of the first six months of the fiscal year ending March 31.
more
2019/11/05 | CORPORATE

Sysmex Wins Awards in 2019 Kinki Local Commendations for Innovations

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received a Minister of Education, Culture, Sports, Science and Technology Prize, and Encouragement Prizes for Inventions, at the Kinki* Local Commendation for Inventions, sponsored by the Japan Institute of Invention and Innovation.
more
2019/11/01 | CORPORATE

Sysmex and OPTiM Reach a Basic Agreement on the Establishment of a Joint Venture to Accelerate the Commercialization of Digital Medicine to Support Next-Generation Healthcare and Diagnostics

Aiming toward the Early-Stage Provision of Platforms and Applications Related to Digital Medicine
more
2019/10/30 | CORPORATE

Industry, Government and Academia Jointly Establish a General Incorporated Association to Promote the Bioresource Business

Jointly Established by Kobe University, the City of Kobe, the Foundation for Biomedical Research and Innovation at Kobe, and Sysmex
more
2019/10/02 | CORPORATE

Knowledge Is Power - Celebrating 10 Years of Sysmex Academy and More

Medical diagnostics company Sysmex Europe GmbH celebrates the 10th anniversary of the Sysmex Academy in October. Sysmex is the only company to have such a longstanding education system in place for both employees, distributors, and later on, end-customers.
more
2019/09/19 | PRODUCT

Sysmex Launches Caresphere™ QM, an Operational Support System for Testing Quality Management

Realizing the Operation of High-Quality Clinical Laboratories through our New Caresphere™ Solution
more
2019/09/17 | CORPORATE

Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Fourth Consecutive Year

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the fourth consecutive year.
more
2019/09/06 | CORPORATE

Sysmex Europe GmbH wins the Silver Award for ‘Best Customer Training Program’ from the 2019 Brandon Hall Group Excellence in Learning Awards

The nomination was based on the customer learning portal – Sysmex Academy – that would supplement the face-to-face training with a broad selection of digital training media and live webinars.
more
2019/09/03 | CORPORATE

Japan’s First Automated Hematology Analyzer Registered by the National Museum of Nature and Science as “Essential Historical Material for Science and Technology”

-Using Unique Technology to Cultivate True Automation in Blood Cell Counting-
more
2019/08/29 | CORPORATE

Hamburg leaders visited Sysmex Corporation in Kobe

At the end of August, a delegation of high-ranking representatives, including Hamburg’s First Mayor Dr Peter Tschentscher, spent one day in Kobe as part of their tour of Japan and China.
more
2019/07/19 | PRODUCT

Liquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, the OncoBEAM™ RAS CRC and the Idylla ctKRAS Mutation Test from the BioCartis Group NV.
more
2019/06/04 | PRODUCT

World Anti-Doping Agency Coordinates Global Implementation of Sysmex Analyzers at All Blood Laboratories

Contributing to Clean and Fair Sports Management by Enhancing the Quality of Doping Tests
more
2019/05/30 | PRODUCT

Sysmex Inostics OncoBEAM™-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations in 183 NSCLC patients in comparison study

Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer Institute (Lyon, France) comparing the performance of Sysmex Inostics BEAMing (beads, emulsion, amplification, and magnetics) assay for EGFR resistance mutations (OncoBEAM-EGFR) to a next-generation sequencing assay (56G Oncology Panel from Swift Biosciences) in non-small cell lung cancer (NSCLC) patients with EGFR sensitizing mutations under first-line tyrosine kinase inhibitor (TKI) therapy.
more
2019/05/28 | PRODUCT

Sysmex Inostics’ SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM™ enhanced digital PCR technology for detection of mutations in circulating tumor DNA

Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 meeting in Atlanta, Georgia demonstrate how Sysmex Inostics’ novel SafeSEQ ER+/HER2- breast cancer panel can detect clinically relevant mutations in circulating tumor DNA (ctDNA) from patients with metastatic breast cancer with sensitivity equivalent to Sysmex’s highly clinically validated OncoBEAM liquid biopsy testing.
more
2019/05/08 | CORPORATE

Promoting Business Process Restructuring through Digitalization to Reinforce Corporate Foundations and Create New Value

To achieve business process restructuring, we will construct a digital foundation for the corporate management functions that underpin the Group management foundation, as well as for the value chain encompassing research and development, procurement and logistics, manufacturing, and sales and service.
more
2019/05/08 | CORPORATE

Sysmex Opens Technopark East Site, a Bio-Diagnostic Reagent Base

Strengthening Diagnostic Reagent Functions through an Integrated Structure from the Development of Substances to the Development, Production and Distribution of Bio-Diagnostic Reagents
more
2019/04/25 | PRODUCT

Sysmex Obtains CE Certification for Automated Hematology Analyzer XN-31, Which Has an Automatic Measurement Function for Red Blood Cells Infected by Malaria Parasites

Contributing to the Early Detection and Treatment of Malaria through Standardized and More Efficient Malaria Testing
more
2019/03/01 | CORPORATE

Sysmex to Be Special Sponsor of the Kobe Marathon 2019

-We are pleased to have sponsored this exciting event since its inception in 2011-
more
2018/07/11 | CORPORATE

Clinical evaluation of Sysmex Inostics’ plasma NGS liquid biopsy technology to complement mammography when screening for early stage breast cancer presented at the 2018 ASCO annual meeting

more
2018/01/22 | CORPORATE

A fondo: Comparación de los resultados obtenidos en los análisis de biopsias líquidas OncoBEAM RAS CRC e Idylla ctKRAS para la detección de la mutación KRAS presentados en la reunión GI de la ASCO en 2018

more
2018/01/17 | CORPORATE

Comparación de los resultados obtenidos con OncoBEAM™ RAS CRC y el test Idylla ct KRAS presentados en la reunión ASCO GI 2018

more
Sysmex España S.L.
Frederic Mompou
4B Planta 2
08960 – Sant Just Desvern
España
(+34) 93 423 62 31
(+34) 934 261 479
info@sysmex.es
Servicios
Social Media
Copyright © Sysmex Europe SE. All rights reserved.